Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 10, 2007 (April 9, 2007)

Endo Pharmaceuticals Holdings Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-15989   13-4022871

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Company

Identification No.)

 

100 Endo Boulevard, Chadds Ford, PA   19317
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (610) 558-9800

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On April 9, 2007, the Registrant announced that Carol A. Ammon, founder and Chairman of the Board of Directors, intends to retire effective May 30, 2007, and accordingly, will not run for re-election to the Registrant’s Board of Directors. The Registrant also announced that Roger H. Kimmel, an independent director of the Registrant since 2000, has been appointed by the Board of Directors to serve as Chairman of the Board, effective May 30, 2007. Mr. Kimmel also serves as a member of the Registrant’s Audit Committee and as Chairman of the Registrant’s Nominating and Governance Committee. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(a) Financial Statements of Business Acquired.

Not applicable.

 

(b) Pro Forma Financial Information.

Not applicable.

 

(c) Shell Company Transactions

Not applicable.

 

(d) Exhibits.

 

Exhibit Number  

Description

99.1   Press Release of Endo Pharmaceuticals Holdings Inc., dated April 9, 2007.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

ENDO PHARMACEUTICALS HOLDINGS INC.

(Registrant)

By:   /s/ CAROLINE B. MANOGUE
  Name:   Caroline B. Manogue
  Title:   Executive Vice President, Chief Legal Officer & Secretary

Dated: April 10, 2007


INDEX TO EXHIBITS

 

Exhibit Number  

Description

99.1   Press Release of Endo Pharmaceuticals Holdings Inc., dated April 9, 2007.